search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Diagnostics


outcomes. UKHSA provides national guidance on antiviral treatment and prophylaxis for seasonal influenza, with annually updated recommendations and an explicit recognition that clinical diagnosis can be challenging when other viruses co-circulate. This is why rapid confirmation of a disease can be valuable when embedded within a defined clinical management or diagnostic pathway when combined with clinical judgement or infectious disease specialist advice.


Rapid diagnostics support timely treatment


decisions for eligible cohorts and reduce unnecessary treatment plans, such as cautionary antibiotics in the presence of influenza-like symptoms or prevent antibiotic prescriptions with delayed dispensing in a more likely probability of viral pathogen causes for acute sore throat presentations. It can also support infection prevention and control decisions, especially when ARIs continue to drive demand across the systems; all while supporting patient trust in decision making, preventing them seeking additional opinions in A&E. In urgent and primary care, this translates


into validated management and discharge decisions when safe to do so, and earlier escalation when there are signs of decline or deterioration. The operational benefit is fewer precautionary referrals. The clinical benefit is a decision that is robustly quantified, transparent, and more consistent. The patient benefit is a plan that is clearer, with focused safety netting and appropriate treatment delivered sooner.


Why embedding point-of-care testing is challenging in community care In my experience, funding remains a primary barrier, often due to misalignment between commissioning scope, provider readiness, and access to time-limited funding mechanisms. Programmes fail in delivery less often because of analytical performance but more often because the system does not resolve the key practical issues: ownership, workforce, estates, digital integration, and governance; but moreover, a lack of agile funding and redistribution. One consistent implementation lesson is that enthusiasm is rarely the limiting factor. Adoption tends to accelerate when system- wide operational and clinical leaders can point to real world evidence from comparable services showing pathway impact on decisions, flow, and escalation. I would debate that commissioners and governing bodies prefer the most cost-effective community models. Subsequently, this creates overly


Rapid diagnostics support timely treatment decisions for eligible cohorts and reduce unnecessary treatment plans, such as cautionary antibiotics.


complex programme expectations, often spanning outcomes, flow, access, and system efficiency, which can dilute implementation and focus.


NHS England urgent community care guidance is explicit that safe out-of-hospital care depends on effective governance and appropriate clinical decision making. Ownership ambiguity is therefore not a minor operational issue; it is a governance risk. 1. Ownership is the first challenge. Who owns quality and training? Who owns the pathway


decisions? Who owns the operational response when demand surges? Without clear ownership, practice becomes variable, and confidence in the deployment erodes.


2. Workforce challenges. Staffing is continually under pressure in winter. Skill mix changes. Inexperienced staff rotate in. Sustaining competency and consistent actions requires a clear training model, time to develop skills, defining roles or scope of practice, and escalation rules that work in hours, as well as evenings and weekends.


Introducing Unifoam


Powered by chlorine dioxide. Clinically proven to reduce CPE in hospital drains.


EFFECTIVE AGAINST CPE AND BIOFILMS


ELIMINATES ODOURS


10-MIN CONTACT TIME


Don’t wait for your next outbreak


Contact us today


REACHING WHERE OTHERS CAN’T


Use biocides safely. Always read the label and product information before use.


November 2026 I www.clinicalservicesjournal.com 43


t


Copyright © Tristel Solutions Limited Mkt-Adv-3804 - 07/Oct/2026 - V1


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71